Lupin Limited announced that VISUfarma B.V., a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with Visus Therapeutics Inc. U.S.A., a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited. This partnership provides VISUfarma the exclusive rights to undertake regulatory activities, commercialization, marketing, promotion, distribution and sale of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, a proprietary ophthalmic product indicated for the treatment of presbyopia in adults, in the European Union, the United Kingdom, Switzerland, Norway, and Iceland.

Under the agreement, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus, individually or collectively, will also be eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based on net sales.

Tenpoint is advancing commercialization of Yuvezzi in the United States following its recent US Food and Drug Administration approval. It will continue to execute its plans for regulatory applications for Yuvezzi in other key regions worldwide.